Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 15/20 | 0.99 |
| ▸ | CYSLTR2 | Q9NS75 | 14/20 | 0.99 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 1/20 | 0.99 |
| ▸ | RECQL | P46063 | 1/20 | 0.99 |
| ▸ | BLM | P54132 | 1/20 | 0.99 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | EGFR | P00533 | 1/20 | 0.99 |
| ▸ | ESR1 | P03372 | 1/20 | 0.99 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.99 |
| ▸ | FYN | P06241 | 1/20 | 0.99 |
| ▸ | PGR | P06401 | 1/20 | 0.99 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.99 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.99 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.99 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.99 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.99 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL4752437 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL27474743 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL125179 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL625297 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL15375392 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4788144 | 1.00 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4487 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4486 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL22207045 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL21635556 | 0.99 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6367 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070907-A | Non-steroidal anti-inflammatory drug freeze-dried orally disintegrating tablet and preparation method thereof | 北京阳光诺和药物研究股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-12539296-B2 | Montelukast for the treatment of erosive hand osteoarthritis | FARMALÍDER, S.A. (ES) | 2026-02-03 | — | — | US | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4633613-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH S.A. (ES) | 2025-10-22 | — | — | EP | claimed |
| US-12383547-B2 | Methods of treatment for a kidney disease | VANDERBILT UNIVERSITY (US) | 2025-08-12 | — | — | US | claimed |
| CN-118598781-B | Preparation method of key intermediate of montelukast sodium | 迪嘉药业集团股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | claimed |
| US-12295992-B2 | Use of ALDH1A and agonist, catalyst and inhibitor thereof | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2025-05-13 | — | — | US | claimed |
| WO-2001032163-A1 | NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | claimed |
| US-6221880-B1 | IN COMBINATION ANTAGONISTS OF NEUROKININ RECEPTORS AND ANTAGONISTS OF LEUKOTRIENE RECEPTORS | SCHERING CORPORATION | 2001-04-24 | — | — | US | claimed |
| EP-1014972-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSION | Merck & Co., Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| WO-2000021564-A1 | COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES | SCHERING CORPORATION (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0971587-A1 | QUINOLINE LEUKOTRIENE ANTAGONISTS | Merck & Co., Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| CN-1210465-A | Methods of treatment and pharmaceutical compositions | MERCK & CO INC (US) | 1999-03-10 | — | — | CN | claimed |
| WO-1998039970-A1 | QUINOLINE LEUKOTRIENE ANTAGONISTS | MERCK & CO., INC. (US) | 1998-09-17 | — | — | WO | claimed |
| EP-0859600-A1 | NEW TECHNOLOGY FOR WET GRANULATION | MERCK FROSST CANADA INC. (CA) | 1998-08-26 | — | — | EP | claimed |
| WO-1997028797-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSION | MERCK & CO., INC. (US) | 1997-08-14 | — | — | WO | claimed |
| WO-1997016173-A1 | NEW TECHNOLOGY FOR WET GRANULATION | MERCK FROSST CANADA INC. (CA) | 1997-05-09 | — | — | WO | claimed |